MergerLinks Header Logo

Announced

Completed

Pfizer completed the acquisition of Therachon for c. $810m.

Synopsis

Pfizer completed the acquisition of Therachon Holding, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome for $340m upfront with an additional $470m. Achondroplasia can result in serious cardiovascular, neurological and metabolic complications for approximately 250k people worldwide. There are currently no approved treatments for achondroplasia. “At Pfizer, our strategy is focused on advancing the most promising science in the world, regardless of whether it is found inside or outside of our labs. By acquiring Therachon, we hope to leverage Pfizer’s leading scientific and development capabilities to more rapidly advance this potentially promising therapy for people with achondroplasia,” Mikael Dolsten, Pfizer Chief Scientific Officer and President, Worldwide Research, Development, and Medical.

Show Details & Financials

Market Context

Sort

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US